NovaBay Pharmaceuticals, Inc.

AMEX: NBYHealthcare / Biotechnology / USA
1.97+0.0100+0.51%Vol 3 522 0781Y Perf -22.35%
Jun 19th, 2019 16:00
BID1.97 ASK1.98
Open1.83 Previous Close1.96
Pre-Market1.93 After-Trading1.91
 -0.04 -2.03%  -0.06 -3.05%
Target Price
1.00 
Analyst Rating
— 0.00
Potencial %
-49.24 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
     22.03
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
     21.01
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)37 
Earnings Rating
Buy
Price Range Ratio 52wk %
45.67 
Earnings Date
6th Aug 2019

Today's Price Range

1.832.24

52wk Range

0.23004.04

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Month
462.86%
3 Months
43.80%
6 Months
98.99%
1 Year
-22.35%
3 Years
-27.84%
5 Years
-90.39%

Name / TickerPriceChg.Chg.%
NBY1.970.01000.51
AAPL197.87-0.5800-0.29
GOOG1 102.33-1.2700-0.12
MSFT135.690.53000.39
XOM75.32-0.4200-0.55
WFC45.65-0.4500-0.98
JNJ140.450.22000.16
FB187.48-0.9900-0.53
GE10.33-0.0900-0.86
JPM109.91-0.8000-0.72
Earnings HistoryEstimateReportedSurprise %
Q01 2019--0.24-
Q04 2018-0.14-0.0935.71
Q03 2018-0.09-0.11-22.22
Q02 2018-0.12-0.15-25.00
Q01 2018-0.07-0.14-100.00
Q04 2017-0.050.02140.00
Q03 2017-0.09-0.16-77.78
Q02 2017-0.12-0.118.33
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.18-20.00Negative
6/2019 QR-0.0650.00Positive
12/2019 FY-0.2925.64Positive
12/2019 FY-0.1167.65Positive
Next Report Date6th Aug 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume3 522 078
Shares Outstanding (in ths.)18 992
Trades Count4 754
Dollar Volume6 487 159
Avg. Volume1 346 597
Avg. Weekly Volume4 451 202
Avg. Monthly Volume6 525 735
Avg. Quarterly Volume2 441 235
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Hold
3.00

NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company. The company develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eyecare market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). NovaBay develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

CEO: Justin M. Hall

Teplephone: +1 510 899-8800

Address: 2000 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

43%57%

Bearish Bullish

56%44%

News